These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25292430)

  • 1. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
    De Strooper B; Chávez Gutiérrez L
    Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
    Cummings J
    Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
    [No Abstract]   [Full Text] [Related]  

  • 4. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from a failed γ-secretase Alzheimer trial.
    De Strooper B
    Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
    Hopkins CR
    ACS Chem Neurosci; 2010 Aug; 1(8):533-4. PubMed ID: 22778845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. γ-Secretase inhibitors and modulators.
    Golde TE; Koo EH; Felsenstein KM; Osborne BA; Miele L
    Biochim Biophys Acta; 2013 Dec; 1828(12):2898-907. PubMed ID: 23791707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
    Schor NF
    Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulators and inhibitors of gamma- and beta-secretases.
    Schmidt B; Baumann S; Narlawar R; Braun HA; Larbig G
    Neurodegener Dis; 2006; 3(4-5):290-7. PubMed ID: 17047370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
    Doody RS; Raman R; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; He F; Sun X; Thomas RG; Aisen PS; ; Siemers E; Sethuraman G; Mohs R;
    N Engl J Med; 2013 Jul; 369(4):341-50. PubMed ID: 23883379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
    Trechot P; Schmutz JL
    Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.
    Rosenberg PB; Lanctôt KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R
    J Alzheimers Dis; 2016 Aug; 54(1):373-81. PubMed ID: 27567808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
    Henley DB; May PC; Dean RA; Siemers ER
    Expert Opin Pharmacother; 2009 Jul; 10(10):1657-64. PubMed ID: 19527190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
    Henley DB; Sundell KL; Sethuraman G; Dowsett SA; May PC
    Curr Med Res Opin; 2014 Oct; 30(10):2021-32. PubMed ID: 24983746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.